Arthritis Treatment Articles & Analysis
15 news found
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...
As an example, our chitosan can help with advanced arthritis when other treatments have been ineffective.’ F.B.: ‘The product we are offering can be less allergenic than animal-based products. It can replace hyaluronic acid, a product that has long been used to combat arthritis and for other applications. However, the effectiveness ...
Chernoff will be invaluable as we advance our rheumatoid arthritis program through the U.S. pivotal study,” commented Murthy Simhambhatla, PhD, President and Chief Executive Officer of SetPoint Medical. ...
This achievement is significant in that it will be the first global clinical trial among the microbiome treatments for rheumatoid arthritis and NASH indications. The most noteworthy part is that LB-P6 has no toxic effects, even after long-term administration, as no side effects were found compared to existing rheumatoid arthritis ...
The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “inflammatory reflex,” for rheumatoid arthritis (RA), Crohn’s disease and other chronic autoimmune diseases as a safe, cost-effective alternative to drugs and biologics. “SetPoint is reshaping the treatment ...
The COV-BARRIER results further validate BenevolentAI’s AI-derived hypothesis, first published in early February 2020, which prompted additional global trials and investigations into its efficacy as a treatment for critically ill COVID-19 patients. In the COV-BARRIER study, baricitinib was given in addition to the standard of care, which included dexamethasone in the ...
Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. ...
The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially efficacious, yet less immunosuppressive option. ...
The patients were enrolled in two phases: Stage 1 (3 patients) was open-label, and Stage 2 (11 patients) was randomized and sham controlled, with the sites and patients blinded to treatment assignment. The primary outcome was treatment-emergent incidence rates of adverse events. ...
The patients were enrolled in two phases: Stage 1 (3 patients) was open-label, and Stage 2 (11 patients) was randomized and sham controlled, with the sites and patients blinded to treatment assignment. The primary outcome was treatment-emergent incidence rates of adverse events. ...
Food and Drug Administration (FDA) to study its proprietary bioelectronic platform in patients with rheumatoid arthritis (RA). The multicenter, double-blind, randomized, sham controlled pivotal trial will enroll up to 250 patients at 40 sites across the U.S. ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. ...
SetPoint Medical’s bioelectronic medicine platform is intended to offer patients and providers a treatment alternative for rheumatoid arthritis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. ...
The multicenter, double-blind, randomized controlled U.S. pilot study evaluated the safety and tolerability of SetPoint’s proprietary wireless microregulator device for the treatment of drug-refractory RA patients. SetPoint completed enrollment in October 2018 and will present results for the primary endpoint at 12 weeks. Details of the oral presentation include: ...